Skip to main navigation Skip to search Skip to main content

Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Epub 2024 Aug 29. PMID: 39213982 (Vaccine (2024) 42(24), (S0264410X24008971), (10.1016/j.vaccine.2024.126215))

Research output: Contribution to journalComment/debate

Abstract

The authors regret the following corrigendum: After the publication of the manuscript, we realised that “dyskariosis” was used for the search in EMBASE instead of the correct spelling “dyskaryosis”. Post-hoc searches in EMBASE both for ‘cervical severe dyskariosis’ and ‘cervical severe dyskaryosis’ search strings resulted in “0” hits retrieved in both cases. Therefore, the final output was not affected by this typo. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number126701
JournalVaccine
Volume47
DOIs
Publication statusPublished - 15 Feb 2025

Bibliographical note

Publisher Copyright:
© 2024 GlaxoSmithKline Biologicals S.A

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Epub 2024 Aug 29. PMID: 39213982 (Vaccine (2024) 42(24), (S0264410X24008971), (10.1016/j.vaccine.2024.126215))'. Together they form a unique fingerprint.

Cite this